Long Noncoding RNA RGMB-AS1 Indicates a Poor Prognosis and Modulates Cell Proliferation, Migration and Invasion in Lung Adenocarcinoma

Ping Li1, Guojun Zhang1*, Juan Li1, Rui Yang1, Shanshan Chen1, Shujun Wu1, Furui Zhang1, Yong Bai1, Huasi Zhao1, Yuanyuan Wang2, Shaozhi Dun3, Xiaonan Chen2, Qianqian Sun2, Guoqiang Zhao2*

1 Department of Respiratory Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China, 2 Department of Microbiology and Immunology, College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan Province, China, 3 Emergency Department, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan Province, China

* gjzhangzzu@126.com (GJZ); zhaogq@zzu.edu.cn (GQZ)

Abstract

Lung cancer is the most common cause of cancer-related mortality worldwide. It is a complex disease involving multiple genetic and epigenetic alterations. The development of transcriptomics revealed the important role of long non-coding RNAs (lncRNAs) in lung cancer occurrence and development. Here, microarray analysis of lung adenocarcinoma tissues showed the abnormal expression of lncRNA RGMB-AS1. However, the role of lncRNA RGMB-AS1 in lung adenocarcinoma remains largely unknown. We showed that upregulation of lncRNA RGMB-AS1 was significantly correlated with differentiation, TNM stage, and lymph node metastasis. In lung adenocarcinoma cells, downregulation of lncRNA RGMB-AS1 inhibited cell proliferation, migration, invasion, and caused cell cycle arrest at the G1/G0 phase. In vivo experiments showed that IncRNA RGMB-AS1 downregulation significantly suppressed the growth of lung adenocarcinoma. The expression of IncRNA RGMB-AS1 was inversely correlated with that of repulsive guidance molecule b (RGMB) in lung adenocarcinoma tissues, and UCSC analysis and fluorescence detection assay indicated that IncRNA RGMB-AS1 may be involved in the development of human lung adenocarcinoma by regulating RGMB expression though exon2 of RGMB. In summary, our findings indicate that IncRNA RGMB-AS1 may play an important role in lung adenocarcinoma and may serve as a potential therapeutic target.

Introduction

Lung cancer is one of the most difficult cancers to treat, and most lung cancers do not show symptoms until they are at advanced stages. Lung cancer is the most common cause of cancer-
related mortality worldwide, and over one-million lung cancer patients die each year [1]. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases of lung cancer, and adenocarcinoma is one of main histological types [2]. Recent research shows that the tumorigenesis and progression of lung adenocarcinoma is a complex process involving multiple genetic and epigenetic alterations [3–5]. Thus, improvements in our understanding of the molecular alterations at multiple levels (genetic, epigenetic, protein expression) and their functional significance have the potential to impact lung adenocarcinoma diagnosis, prevention, prognosis, and treatment.

The development of high throughput DNA sequencing and array based technologies has led to the identification of various classes of non-coding RNAs (ncRNAs) that function as regulators of protein coding genes [6]. There are three types of ncRNAs, namely long ncRNAs, mid-size ncRNAs, and short ncRNAs [7]. Most studies have focused on short ncRNAs, such as microRNAs, which are involved in the regulation of various cellular processes [8–10]. Long ncRNAs (lncRNAs) are rapidly gaining prominence. LncRNAs are longer than 200 nucleotides [6], and have emerged recently as major players in the regulation of various biological and pathological processes, such as the immune response [11], differentiation [12], metabolism [13], and cancer development and progression [14–16]. Increasing evidence suggests that lncRNAs are involved in lung cancer pathogenesis, providing new insight into the biology of this disease. Microarray analysis of lung adenocarcinoma tissues showed abnormal expression of lncRNA RGMB-AS1. However, the role of lncRNA RGMB-AS1 in lung adenocarcinoma remains largely unknown. A related gene, repulsive guidance molecule b (RGMB), is a member of the repulsive guidance molecules (RGMs) and plays a role in many biological activities, such as the local recurrence and distant metastasis of breast cancer [17] and the growth and aggressiveness of prostate cancer cells [18]. In the present study, we further explored the role of lncRNA RGMB-AS1 and the potential underlying mechanism in lung adenocarcinoma.

**Materials and Methods**

**Patients and Tissue Samples**

A total of 110 paired lung adenocarcinoma tissues and adjacent normal tissues (≥3 cm away from tumor) were obtained from patients who received surgical resection of lung adenocarcinoma between 2012 and 2015 in the First Affiliated Hospital of Zhengzhou University. The diagnosis of lung adenocarcinoma was confirmed by histopathology, and none of the patients had received chemotherapy, radiotherapy, or targeted therapy before surgery. The tumor samples and matched adjacent normal tissues were snap-frozen in liquid nitrogen immediately after resection until total RNA and protein extraction. All patients were recruited in accordance with institutional ethics guidelines. Written informed consent was obtained from all subjects.

**Cell Culture and Transfection**

The human lung adenocarcinoma cell lines A549 and SPC-A-1 were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, CA, USA) containing 10% fetal bovine serum (FBS; Gibco, CA, USA), 100 IU/mL penicillin, and 100 μg/mL streptomycin (Invitrogen, CA, USA) at 37°C in a humidified 5% CO2 atmosphere. For transfection, cells were seeded into six-well plates at a density of 5×10^4 cells/well. When cell viability reached approximately 80%, transient transfection was performed using Lipofectamine™2000 (Invitrogen) following the manufacturer’s instructions. Small interfering RNA (siRNA) against lncRNA RGMB-AS1, and control oligonucleotides (negative control, NC) were synthesized by Shanghai Gene-Pharma Co. Ltd (Shanghai, China). Cells from each cell line were subdivided into three groups.
as follows: si-lncRNA group, transfected with siRNA against lncRNA RGMB-AS1; NC group, transfected with negative control oligonucleotides; and an untransfected blank group.

RNA Extraction and Quantitative Real-Time PCR
Total RNA was extracted from the paired lung adenocarcinoma tissues and adjacent normal tissues and from cell lines following the manufacturer’s protocols for each kit. RNA quality was confirmed using a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, USA). An OD$_{260/280}$ of approximately 1.8 is the criterion of acceptable purity. Reverse transcription was achieved by following the manufacturer’s protocols of a First Strand cDNA Synthesis Kit (Qiagen, Germany). The relative levels of lncRNA RGMB-AS1 and RGMB mRNA were determined by quantitative real-time PCR, which was performed using the ABI Power SYBR$^{\text{TM}}$ Green PCR Master Mix (Applied Biosystems, USA). The relative expression levels of lncRNA RGMB-AS1 and RGMB mRNA were calculated using the 2$^{-\Delta\text{Ct}}$ method and normalized to GAPDH.

Cell Counting Kit-8 Assay
The cell counting kit-8 (CCK-8) assay was performed according to the manufacturer’s protocols (CCK-8; Dojindo, Japan). The three experimental groups (si-lncRNA, NC and Blank) of A549 and SPC-A-1 cells were seeded into 96-well plates at a density of $1 \times 10^4$ cells/well, with three replicate wells per group. The cells were cultured for 3 days in succession. Then the CCK-8 solution was added to each well at 10 $\mu$L/well, and incubated for an additional 3 h at 37°C. The optical density (OD) was measured at a wavelength of 450 nm (OD$_{450}$) to estimate cell proliferation among different groups. The experiment was independently repeated in triplicate.

Colony Formation Assay
Colony formation assay was performed to detect the clone formation ability and compare the difference among the three experimental groups (si-lncRNA, NC and Blank) of A549 and SPC-A-1 cells respectively. In 10-cm dishes, we plated the bottom layer of agar and then the upper layer of agar containing different transformed cells and blank cells. Incubated for 2 weeks in succession, the upper layer of agar containing cells were stained with crystal violet and then the colonies were counted in each dish to estimate the plating efficiency among different groups. Those containing $>50$ cells were scored as surviving colonies. The experiment was independently repeated in triplicate.

Wound Healing Assay
Wound healing assay was performed to detect the migration ability and compare the difference among the three experimental groups (si-lncRNA, NC and Blank) of A549 and SPC-A-1 cells respectively. 2x10$^5$ cells/well were plated onto 6-well plates. When cells were completely adherent, a sterile 200 $\mu$L pipette tip was used to scratch a straight line through the cell layer in each well. With fresh medium the cells were incubated in the incubator for 24 h and then photographed to estimate the changes of migration ability in different groups. Assays were repeated three times for each clone.

Transwell Assay
Transwell assay was performed to detect the invasion ability and compare the difference among the three experimental groups (si-lncRNA, NC and Blank) of A549 and SPC-A-1 cells respectively. 200 $\mu$L of 48 h post-transfected cells suspension with the concentration as 2x10$^5$ cells/mL was added on the upper chamber of a 24-well Transwell Permeable Support (Costar,
USA) with 8 \( \mu \)m pores. Meanwhile, 500 \( \mu \)L of DMEM containing 10% FBS was put into the lower chamber. And then the plates were incubated in the incubator for 48 h. Five replicate wells were used in per group. After incubation, the medium was removed from the upper chamber and each group cells in the upper chamber were scraped off with a cotton swab. The number of cells invading the matrigel in each group was fixed with methanol, stained with hematoxylin, mounted, and dried at 80°C for 30 min. Then we counted cells in three randomly selected fields under an inverted microscope (200× magnification) to estimate the changes of invasion ability in different groups. The experiment was independently repeated in triplicate.

**Cell Cycle Analysis**

Flow-cytometric analyses were performed to assess cell cycle progression. A549 and SPC-A-1 cells were trypsinized 48 h after transfection, washed with phosphate-buffered saline (PBS; Gibco, CA, USA), and fixed in 75% ice-cold ethanol at 4°C overnight. After rehydrating with ice-cold PBS, the cells were digested by RNase (0.1 g/l) for 2–3 h at 37°C and stained with propidium iodide for 30 min at 4°C in the dark. Data were collected using a BD XCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). The experiment was independently repeated in triplicate.

**Xenograft Tumor Growth Assay**

Luciferase-tagged A549 and SPC-A-1 cells were stably transfected with siRNA against lncRNA RGMB-AS1 (si-lncRNA group) or scramble (NC group) by lentivirus. Then, 2×10^6 transfected cells were subcutaneously inoculated into the dorsal scapular region of 6-week-old BALB/c nude mice which were purchased from Henan Experimental Animals Centre (Zhengzhou, China). The mice were anesthetized with an inhalation of sevoflurane during the subcutaneous injection. Every group included five nude mice for observation. The luciferase signals were observed after 1, 2, 3, and 4 weeks with the Xenogen IVIS \(^{\text{®}}\) Imaging System (Xenogen, Caliper Life Sciences, Boston, USA). The Living Image In Vivo Imaging 3D software (Xenogen) was then used to analyze the data obtained. These study protocols were approved by the Animal Experimental Ethics Committee of Zhengzhou University.

**Protein Extraction and Western Blotting**

Total protein was isolated from tissues or transfected cells. Protein concentration was determined using BCA protein quantitation kit. Protein (50\( \mu \)g of each sample) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and transferred electrophoretically onto polyvinylidene difluoride membranes (Whatman, Maidstone, UK). Then, the membranes were blocked in 5% skim milk for 1 h, washed three or four times with Tris-buffered saline containing 20% Tween 20 (TBST) at room temperature, and incubated with the primary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA): rabbit anti-human RGMB (1:500) or Ki67 (1:500) at 4°C overnight. Following extensive washing with TBST, the membranes were then incubated with secondary antibody (goat anti-rabbit IgG, 1:1000, Santa Cruz Biotechnology) at room temperature for 1 h, washed with TBST four times (15 min each), the immunoreactivity was visualized by enhanced chemiluminescence. GAPDH (Santa Cruz Biotechnology) served as an endogenous control. The experiment was independently repeated in triplicate.
Vector Construction and Fluorescence Detection Assay

Based on the UCSC analysis of IncRNA RGMB-AS1 and RGMB, part of the first exon (Exon1) and the second exon (Exon2) of RGMB have the region that can be combined with the IncRNA RGMB-AS1. The regions of Exon1 and Exon2 were amplified from human genomic DNA and inserted into the pEGFP-N3 vector (Promega, Madison, WI, USA) with Hind III and BamHI sites to construct the recombinant plasmids pEGFP-N3-Exon1 and pEGFP-N3-Exon2, respectively. The third exon of IncRNA RGMB-AS1 was also amplified from human genomic DNA and inserted into the pSilencer 3.1 vector (Promega) with BamHI and Hind III sites to construct the recombination plasmid pSilencer-RGMB-AS1. A549 cells were seeded into ordinary 96-well plates (Corning, New York, USA) and 96-well plates for fluorescence detection, and then transfected with 200 ng of pEGFP-N3-Exon1 or pEGFP-N3-Exon2 or co-transfected with pSilencer-RGMB-AS1 or pSilencer 3.1 using Lipofectamine™2000 (Invitrogen). After 48 h, transfection efficiency was assessed by fluorescence microscopy and using a fluorescence microplate reader. To determine transfection efficiency, changes of fluorescence in every group were observed by fluorescence microscopy. Relative quantitative analysis was performed using an FL600 Fluorescence Microplate reader (Bio-Tek Instrument, Winooski, Vermont) with KC4 data reduction software on an external PC controlling reader function and data capture (Bio-Tek Instruments). Fluorescence was determined using a 485 nm, 20 nm bandpass excitation filter and a 530 nm, 25 nm bandpass emission filter. Cells were subdivided into six groups as follows: For Exon1, Exon1-I: cells transfected with pEGFP-N3-Exon1 only; Exon1-II: cells co-transfected with pEGFP-N3-Exon1 and pSilencer 3.1; Exon1-III: cells co-transfected with pEGFP-N3-Exon1 and pSilencer-RGMB-AS1; for Exon2, Exon2-I: cells transfected with pEGFP-N3-Exon2 only; Exon2-II: cells co-transfected with pEGFP-N3-Exon2 and pSilencer 3.1; Exon2-III: cells co-transfected with pEGFP-N3-Exon2 and pSilencer-RGMB-AS1. The experiment was also independently repeated in triplicate.

Statistical Analysis

All analyses were performed using SPSS17.0 software. Data were expressed as the mean ± standard deviation (SD). One-way analysis of variance (ANOVA) was used to analyze the significance between groups. Multiple comparisons were made using the least significant difference test when the probability for ANOVA was statistically significant. Statistical significance was set at $P<0.05$.

Results

LncRNA RGMB-AS1 Is Upregulated and RGMB Is Downregulated in Lung Adenocarcinoma

The expression levels of IncRNA RGMB-AS1 and RGMB mRNA were evaluated by qRT-PCR in 110 paired lung adenocarcinoma tissues and adjacent normal tissues. The expression of IncRNA RGMB-AS1 was significantly higher in lung adenocarcinoma tissues than in adjacent normal lung tissues (Fig 1A). The clinicopathological characteristics of 110 patients, including age, gender, tumor differentiation, TNM stage and lymph node metastasis, are presented in Table 1. The expression of IncRNA RGMB-AS1 in cancer tissues was higher in the poorly differentiated group than in the well differentiated and moderately differentiated groups ($P < 0.05$; Fig 1B). LncRNA RGMB-AS1 expression in cancer tissues was associated with TNM stage and lymph node metastasis ($P < 0.05$; Fig 1C and 1D). Conversely, RGMB mRNA expression was generally downregulated in lung adenocarcinoma tissues (Fig 1E). In contrast to IncRNA RGMB-AS1, RGMB mRNA expression was significantly lower in the poorly
differentiated group or in patients with lymph node metastasis or TNM stage III (P < 0.05; Fig 1F–1H). LncRNA RGMB-AS1 and RGMB mRNA expression was not associated with gender, age or pathological type (P > 0.05; Table 1). Pearson’s correlation analysis indicated that the expressions of lncRNA RGMB-AS1 and RGMB mRNA were inversely correlated (R^2 = 0.734, Fig 1I). Furthermore, western blotting showed that RGMB was downregulated in lung adenocarcinoma (P < 0.05; Fig 1J and 1K). These data indicate that lncRNA RGMB-AS1 and RGMB expression are negatively correlated and may be involved in the progression of lung adenocarcinoma.

Silencing of lncRNA RGMB-AS1 Inhibits Proliferation in A549 and SPC-A-1 Cells

A549 and SPC-A-1 cells were transfected with siRNA against lncRNA RGMB-AS1 (si-lncRNA group) or negative control oligonucleotides (NC group). qRT-PCR results showed that lncRNA RGMB-AS1 expression was significantly decreased but RGMB expression increased in the si-
IncRNA group compared with the NC and Blank groups \( (P < 0.05, \text{Fig } 2A \text{ and } 2B) \), which not only verified the reliable knockdown effect of siRNA against IncRNA RGMB-AS1, but also further indicated the inverse correlation between RGMBAS1 and RGMB. Then, the CCK-8 assay was performed to evaluate the effect of lncRNA RGMB-AS1 silencing on the proliferation activity of A549 and SPC-A-1 cells. The results showed that the OD450 values for the siRNA group on days 2, 3 and 4 were significantly decreased in both A549 and SPC-A-1 cells \( (P < 0.05, \text{Fig } 2C \text{ and } 2D) \) in comparison with the control groups \( (P > 0.05) \). In the colony formation assay, the colony-forming activity of the si-lncRNA group was lower than that of the NC and Blank groups \( (P < 0.05, \text{Fig } 2E \text{ and } 2F) \). There were no significant differences between the NC and Blank groups \( (P > 0.05) \). These data indicate that lncRNA RGMB-AS1 can affect the proliferation capacity of A549 and SPC-A-1 cells.

Silencing of IncRNA RGMB-AS1 Can Lead to Cell Cycle Arrest in A549 and SPC-A-1 Cells

To further explore the role of IncRNA RGMB-AS1 in lung adenocarcinoma cells, cell cycle analysis was performed in A549 and SPC-A-1 cells transfected with siRNA against IncRNA RGMB-AS1 or negative control oligonucleotides and a blank group by three independent repeated experiments. Flow cytometric analysis showed a marked increase in the percentage of cells in the G0/G1 phase and a reduction in the percentage of cells in the S phase in the si-lncRNA group in A549 cells \( (P < 0.05, \text{Fig } 3A \text{ and } 3B) \). No significant changes were observed in the percentage of cells in the G0/G1 or S phase in the NC and Blank groups \( (P > 0.05) \). Flow cytometric analysis of SPC-A-1 cells showed the same tendency, with a marked increase in the

| Clinicopathological factor | n   | LncRNA RGMB-AS1 expression \( (2^{-\Delta\text{Ct}}) \) | RGMB mRNA expression \( (2^{-\Delta\text{Ct}}) \) |
|----------------------------|-----|---------------------------------|----------------------------------|
| Gender                     |     | Median ± SD                     | \( P \)                           |
| Male                       | 60  | 0.0614±0.0542                   | 0.407                            | 0.4026±0.1747                   | 0.825 |
| Female                     | 50  | 0.0699±0.0536                   |                                  | 0.4100±0.1721                   |       |
| Age(years)                 |     |                                 |                                  |                                 |       |
| >60                        | 46  | 0.0560±0.0638                   | 0.129                            | 0.4373±0.1720                   | 0.107 |
| <60                        | 64  | 0.0719±0.0587                   |                                  | 0.3834±0.1711                   |       |
| Differentiation            |     |                                 |                                  |                                 |       |
| Well                       | 29  | 0.0285±0.0291                   | 0.003\*                         | 0.5172±0.1587                   | 0.002* |
| Moderate                   | 63  | 0.0579±0.0381                   | 0.3979±0.1578                    |                                 |       |
| Poor                       | 18  | 0.1504±0.0417                   | 0.2550±0.1165                    |                                 |       |
| TNM stage                  |     |                                 |                                  |                                 |       |
| I+II                       | 68  | 0.0371±0.0335                   | 0.000**                         | 0.4602±0.1799                   | 0.001* |
| III                        | 42  | 0.1108±0.0494                   | 0.3182±0.1128                   |                                 |       |
| Nodal stage                |     |                                 |                                  |                                 |       |
| Negative                   | 76  | 0.0402±0.0344                   | 0.000**                         | 0.4527±0.1720                   | 0.000c*|
| Positive                   | 34  | 0.1213±0.0471                   | 0.3016±0.1229                   |                                 |       |

*Indicated statistical significance \( (P < 0.05) \);
\( a^* \) Indicated \( P = 0.000189870 \);
\( b^* \) Indicated \( P = 0.0005060830 \);
\( c^* \) Indicated \( P = 0.00015108561 \).

doi:10.1371/journal.pone.0150790.t001

The Role of Long Noncoding RNA RGMB-AS1 in Lung Adenocarcinoma

PLOS ONE | DOI:10.1371/journal.pone.0150790 March 7, 2016 7 / 17
percentage of G0/G1 phase cells and a decrease the percentage of S phase cells in the si-lncRNA group (P < 0.05, Fig 3C and 3D), with no changes in the NC and Blank groups. This indicates that lncRNA RGMB-AS1 plays a role in cell cycle progression in lung adenocarcinoma, supporting the effect of lncRNA RGMB-AS1 on cell proliferation.

Silencing of IncRNA RGMB-AS1 Decreases Migration and Invasion in A549 and SPC-A-1 Cells

To investigate the effect of IncRNA RGMB-AS1 on the migration and invasion of A549 and SPC-A-1 cells, wound healing and transwell assays were performed to determine the migratory and invasive abilities of cells after transfection with siRNA against IncRNA RGMB-AS1. The former assay revealed that the migratory ability of A549 and SPC-A-1 cells in the si-lncRNA
The role of long noncoding RNA RGMB-AS1 in lung adenocarcinoma

A group was lower at 24 h post-wounding compared with both NC and Blank groups (P < 0.05, Fig 4A and 4B). The cell invasion assay showed that the number of invading cells was significantly lower in the siRNA group than in the two control groups in both A549 and SPC-A-1 cells (P < 0.05, Fig 4C and 4D). Cells in the NC and Blank groups were not affected (P > 0.05).

Fig 3. Biological effect of lncRGMB-AS1 downregulation on cell cycle progression in A549 and SPC-A-1 cells. (A and B) Flow cytometric analysis showed a marked increase in the percentage of cells in the G0/G1 phase and a reduction in the percentage of cells in the S phase in the si-lncRNA group in A549 cells (P < 0.05), without significant changes in the NC and Blank groups (P > 0.05). (C and D) Flow cytometric analysis of SPC-A-1 cells showed a marked increase in the percentage of G0/G1 phase cells and a decrease the percentage of S phase cells in the si-lncRNA group (P < 0.05), without significant changes in the NC and Blank groups (P > 0.05). si-lncRNA: cells that were transfected with siRNA of lncRNA RGMB-AS1; NC: cells that were transfected with negative control oligonucleotides, and Blank: cells that were not transfected.

Fig 4. Biological effect of lncRGMB-AS1 downregulation on cell migration and invasion in A549 and SPC-A-1 cells. (A, B) Wound healing assays showed that the migration ability of A549 and SPC-A-1 cells was lower in the si-lncRNA group at 24 h post-wounding than in both NC and Blank groups (P < 0.05). (C) Transwell assays showed that the invasive ability of A549 and SPC-A-1 cells was lower in the si-lncRNA group than in the NC and Blank groups in A549 and SPC-A-1 cells (P < 0.05). (D) Quantitative data of Transwell results in A549 and SPC-A-1 cells. si-lncRNA: cells that were transfected with siRNA of lncRNA RGMB-AS1; NC: cells that were transfected with negative control oligonucleotides, and Blank: cells that were not transfected. *Indicates statistical significance (P < 0.05).
Taken together, these findings suggest that lncRNA RGMB-AS1 plays a role in the migration and invasion capacity of A549 and SPC-A-1 cells.

Silencing of IncRNA RGMB-AS1 Can Inhibit Cell Proliferation in Lung Adenocarcinoma In Vivo

The growth of xenograft tumors was assessed to further examine the tumor-suppressing effect of siRNA against IncRNA RGMB-AS1 on lung adenocarcinoma. In A549 cell tumors, the luciferase signal was clearly lower in si-lncRNA mice than in the control groups at 2, 3, and 4 weeks. The signal intensity in the si-lncRNA group decreased with time ($P < 0.05$, Fig 5A and 5C). A similar trend was observed in mice with SPC-A-1 tumors (Fig 5B and 5D). Next, we detected Ki67 expression in the total protein of xenograft tissues from different groups respectively. Significant differences in Ki67 expression were observed between the si-lncRNA group and the control groups ($P < 0.05$, Fig 5E and 5F). There were no differences in Ki67 expression between NC group and Blank group ($P > 0.05$). The opposite trend was observed in RGMB expression. RGMB expression was statistically significantly higher in the si-lncRNA group.

**Fig 5. Biological effect of lncRGMB-AS1 downregulation on cell proliferation in lung adenocarcinoma in vivo.** (A, C) In mice injected with A549 cells, the luciferase signal was lower in the si-RNA nude mice than in the control groups at 2, 3, and 4 weeks, and the signal intensity became even lower in the si-RNA group with time ($P < 0.05$). (B, D) In mice injected with SPC-A-1 cells, the luciferase signal was lower in the si-RNA nude mice than in the control groups at 2, 3, and 4 weeks, and the signal intensity also became lower in the si-RNA group with time ($P < 0.05$). (E, F) Western blot analysis of Ki67 and RGMB expression in xenograft tissues from the three groups of nude mice. Compared with the control groups, Ki67 was downregulated and RGMB was upregulated in the si-RNA group ($P < 0.05$). si-lncRNA: cells that were transfected with siRNA of lncRNA RGMB-AS1; NC: cells that were transfected with negative control oligonucleotides, and Blank: cells that were not transfected. *Indicated statistical significance ($P < 0.05$).
than in the NC and Blank groups ($P < 0.01$). These data indicated that lncRNA RGMB-AS1 affected the proliferation of lung adenocarcinoma in vivo. Our results indicate that lncRNA RGMB-AS1 may play a tumor-promoting role in lung adenocarcinoma.

**LncRNA RGMB-AS1 Potentially Regulates RGMB Expression through Exon2 of RGMB**

The UCSC database transcription information indicated that lncRNA RGMB-AS1 is located on human chromosome 5 and has two interaction sites in the exon region of RGMB. To verify the interaction between lncRNA RGMB-AS1 and RGMB in lung adenocarcinoma, the recombinant plasmids pEGFP-N3-Exon1, pEGFP-N3-Exon2, and pSilencer-RGMB-AS1 were generated (Fig 6A). The changes of fluorescence in the different groups were analyzed at 48 h after transfection. The fluorescence intensity of the pEGFP-N3-Exon1 group was used as a control to analyze the relative fluorescence intensity in the other groups. For Exon1, the results of fluorescence microscopy and fluorescence microplate reader showed that the fluorescence intensity of cells co-transfected with pEGFP-N3-Exon1 and pSilencer-RGMB-AS1 did not differ from that of cells transfected with pEGFP-N3-Exon1 only or that of cells co-transfected with pEGFP-N3-Exon1 and pSilencer 3.1 ($P > 0.05$, Fig 6B). For Exon2, the fluorescence intensity...
of cells co-transfected with pEGFP-N3-Exon2 and pSilencer-RGMB-AS1 was weaker than that of cells transfected with pEGFP-N3-Exon2 only or that of cells co-transfected with pEGFP-N3-Exon2 and pSilencer 3.1 (P < 0.05, Fig 6C). There was no difference between the fluorescence intensity of cells transfected with pEGFP-N3-Exon2 only and that of cells co-transfected with pEGFP-N3-Exon2 and pSilencer 3.1 (P > 0.05, Fig 6C). These results indicate that lncRNA RGMB-AS1 may downregulate RGMB expression though the exon2 sequence of RGMB.

Silencing of IncRNA RGMB-AS1 Affects the Proliferation and Invasion Abilities of A549 and SPC-A-1 Cells More Significantly than RGMB Overexpression

To further verify the potential relationship between IncRGMB-AS1 and RGMB in lung adenocarcinoma cells, we constructed a pcDNA3.1 (+)/RGMB vector and transfected it into A549 and SPC-A-1 cells (RGMB group). Western blot analysis showed that the expression of RGMB was higher in the RGMB and si-IncRNA groups than in the Blank groups (P < 0.05, Fig 7A). The OD450 values in RGMB cells on days 2, 3 and 4 were significantly decreased compared with those in blank cells, (Fig 7B and 7C). Flow cytometric analysis of cell cycle progression indicated that the proportion of cells in S phase was reduced in the si-IncRNA and RGMB groupsthan in the Blank groups (Fig 7D). Transwell invasion assays demonstrated that the invasive ability was lower in the si-IncRNA group and in the RGMB group (Fig 7E). These data indicate that IncRNA RGMB-AS1 knockdown and RGMB overexpression play the similar roles in the proliferation, migration, invasion of A549 and SPC-A-1 cells. Maybe IncRNA RGMB-AS1 and RGMB are involved in some signaling pathways to affect the progress of lung adenocarcinoma.

![Figure 7](https://example.com/figure7.png)

**Fig 7. Effects of IncRNA RGMB-AS1 silencing and RGMB overexpression on the biological behavior of A549 and SPC-A-1 cells.** (A) RGMB expression was higher in cells transfected with si-IncRNA or pcDNA3.1 (+)/RGMB than in Blank cells (P < 0.05). (B and C) Proliferation rates were lower in cells transfected with si-IncRNA or pcDNA3.1 (+)/RGMB than in Blank cells. (D) Cell cycle arrest was more marked in the si-IncRNA and RGMB groups than in the Blank group cells. (E) Cell invasion ability was higher in the si-IncRNA group and RGMB group than in the Blank group. si-IncRNA: cells that were transfected with siRNA of IncRNA RGMB-AS1; RGMB: cells that were transfected with pcDNA3.1 (+)/RGMB vector, and Blank: cells that were not transfected. *Indicates statistical significance (P < 0.05).
Discussion

Studies on the development and progression of lung cancer should focus on the related mechanism and the potential genes involved, which could be beneficial for the development of treatments against lung cancer. Recent studies point to IncRNAs as new candidate molecules to be incorporated into the arsenal of therapeutic targets in lung cancer. For example, upregulation of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has been found to play an important role in NSCLC and originally identified as a potential marker for metastasis and patient survival in NSCLC, especially in early stages of lung adenocarcinoma in the early years [19, 20]. Along with the further studies on genetic level, MALAT-1 may associate with many genes and maybe some signal pathway to involve in the development of lung cancer[21]. As the summary from Akanksha Khandelwal et al, MALAT-1 regulated the expression and activities of caspase-8, caspase-3, BAX, BCL-2, and BCL-XL to affect cell growth and proliferation, migration and invasion [22]. Another one of cancer-associated IncRNAs, HOTAIR, is well known for its roles in tumor progression such as ever reported bladder cancer, ovarian cancer, cervical cancer and also including NSCLC [23–26]. One study has demonstrated that HOTAIR regulated predicted homeobox protein A5 (HOXA5) expression to involve in lung cancer development[27]. Another studies in lung cancer cells, HOTAIR were not only reported to regulate genes and signaling pathways that can affect tumour differentiation, proliferation, and invasion [26,28], but also regulated the chemosensitivity of NSCLC cells to anticancer drugs [29, 30]. Therefore, IncRNAs represent an emerging player in lung cancer and may become new prognostic biomarkers or therapeutic strategies for lung cancer patients. As a new identified IncRNA, RGMB-AS1 is localized in human chromosome 5 between 98105322 and 98108829 base sites and has been found the abnormal expression in lung adenocarcinoma. However, the involvement of RGMB-AS1 in the development of lung adenocarcinoma remains unknown.

In the our study, the analyses in clinical sample showed that IncRNA RGMB-AS1 was significantly upregulated and correlated with differentiation, TNM stage, and lymph node metastasis. Specifically about differentiation status and lymph node status, we found that IncRNA RGMB-AS1 expression in cancer tissues was higher in the poorly differentiated group and positive lymph node metastasis group than in the well differentiated and moderately differentiated groups and negative group. This suggests that IncRNA RGMB-AS1 plays a role in the progression of lung adenocarcinoma.

As high IncRNA RGMB-AS1 expression was associated with an aggressive tumor phenotype in lung adenocarcinoma, we speculated that IncRNA RGMB-AS1 could play a significant role in tumor biology. By designing synthesizing several siRNAs against IncRNA RGMB-AS1 and negative control oligonucleotides, we transfected them into A549 and SPC-A-1 cellsAnd then performed qRT-PCR assays to find the most effective siRNA sequence and avoid the off-target. We next determined whether IncRNA RGMB-AS1 expression affected cell proliferation, migration, invasion, and cell cycle progression. Our results showed that IncRNA RGMB-AS1 silencing inhibited cell proliferation, migration, and invasion, and caused cell cycle arrest at the G1/G0 phase. Moreover, decreased IncRNA RGMB-AS1 levels significantly suppressed the proliferation of lung adenocarcinoma in vivo. This is in line with our clinical findings that IncRNA RGMB-AS1 was significantly correlated with differentiation degree, tumor stage, and lymphatic metastasis. These results indicated that IncRNA RGMB-AS1 may play a role in the progression of lung adenocarcinoma by affecting cell proliferation, migration and invasion.

LncRNA RGMB-AS1 is a non-coding transcript in the UCSC database. We obtained the details of this gene through the UCSC genome database and analyzed the associated information regarding gene transcripts. Based on the UCSC database transcription information about the
location on human chromosome, the cDNA sequence of RGMB-AS1 is 3508 bp and includes three exons. Further genome analysis showed that lncRNA RGMB-AS1 corresponds to a natural antisense transcript. Another antisense DNA complementary strand of lncRNA RGMB-AS1 encodes RGMB. The UCSC database showed that it was localized on human chromosome 5 between bases 98109606 and 98129556, and the gene name is NM_001012761.2 in the GenBank database. These results suggested the existence of a relationship between lncRNA RGMB-AS1 and RGMB. Our results on the relation of lncRNA RGMB-AS1 and RGMB expression with clinicopathological characteristics indicated that there is an inverse relationship between the expression of lncRNA RGMB-AS1 and that of RGMB. To verify the interaction between them, we constructed the recombinant plasmids pEGFP-N3-Exon1, pEGFP-N3-Exon2, and pSilencer-RGMB-AS1. After transfection for 48 h, the changes of fluorescence were analyzed in the different groups. The results showed that the fluorescence intensity of cells co-transfected with pEGFP-N3-Exon2 and pSilencer-RGMB-AS1 was weaker than that of cells transfected with pEGFP-N3-Exon2 only or cells co-transfected with pEGFP-N3-Exon2 and pSilencer 3.1. However, the fluorescence intensity of cells co-transfected with pEGFP-N3-Exon1 and pSilencer-RGMB-AS1 did not differ from that of cells transfected with pEGFP-N3-Exon1 only or that of cells co-transfected with pEGFP-N3-Exon1 and pSilencer 3.1. To further examine the potential relationship between IncRGMB-AS1 and RGMB in lung adenocarcinoma cells, the pcDNA3.1 (+) / RGMB vector was transfected into A549 and SPC-A-1 cells (RGMB group), and the effect was compared with that of transfection with siRNA against lncRNA RGMB-AS1. The results indicated that silencing of lncRNA RGMB-AS1 and RGMB overexpression have the similar effect on A549 and SPC-A-1 cells, which suggested that lncRNA RGMB-AS1 and RGMB is the valuable target for lung adenocarcinoma therapy. Certainly we can’t ruled out that RGMB-AS1 might affect more than one target mRNA and participate in various signaling pathways. The effect of RGMB may involve many complicated mechanisms. RGMB, also known as DRAGON, is a member of the RGM family, which includes RGMA, RGMB, and RGMC [31]. RGMs are a group of cysteine rich 33 kDa proteins, including an N-terminal signal peptide, a proteolytic cleavage site, a partial von Willebrand factor type D domain, and a glycophasphatidylinositol (GPI) anchor [32, 33]. RGM proteins can function as bone morphogenetic protein (BMP) coreceptors [34–36], which are members of the transforming growth factor beta family of ligands and play a role in many biological activities. In C2C12 myoblasts, a study suggested that a novel molecule(s) expressed on the cell membrane may mediate the signal transduction of DRAGON to suppress BMP signaling [37]. In breast cancer, RGMB affects cell proliferation, adhesion and migration capacity in vitro and acts as a negative regulator through BMP signaling [38]. The present study had limitations, and additional related molecular mechanisms need to be examined. Nevertheless, our results indicated that IncRNA RGMB-AS1 may downregulate RGMB expression though exon2 of RGMB, and further suggest that lncRNA RGMB-AS1 and RGMB could involve in some signaling pathways to affect the development and progression of lung adenocarcinoma. It is necessary to further explore the potential signaling pathways for lung adenocarcinoma therapy.

Conclusions

LncRNA RGMB-AS1 is upregulated in lung adenocarcinoma and associated with differentiation, TNM stage, and lymph node metastasis. Silencing of lncRNA RGMB-AS1 in lung adenocarcinoma cells inhibited cell proliferation in vivo and in vitro, decreased cell migration and invasion, and caused cell cycle arrest at the G1/G0 phase. These effects could be mediated by the modulation of RGMB expression by lncRNA RGMB-AS1. LncRNA RGMB-AS1 may be a novel and valuable therapeutic target in lung cancer.
Acknowledgments

The authors are grateful to all staff at the study centre who contributed to this study.

Author Contributions

Conceived and designed the experiments: GJZ GQZ PL. Performed the experiments: PL RY SSC SJW FRZ YB HSZ. Analyzed the data: PL YYW GJZ GQZ. Contributed reagents/materials/analysis tools: PL JL YYW SZD XNC QQS. Wrote the paper: PL JL YYW SZD XNC QQS.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5–29. doi: 10.3322/caac.21254 PMID: 25559415
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008; 83:584–94. doi: 10.4065/83.5.584 PMID: 18452692
3. Kabbout M, Garcia MM, Fujimoto J, Liu DD, Woods D, Chow CW, et al. ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. Clin Cancer Res. 2013; 19:3383–95. doi: 10.1158/1078-0432.CCR-13-0341 PMID: 23699668
4. Xu C, Xie D, Yu SC, Yang XJ, He LR, Yang J, et al. β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res. 2013; 73:3181–9. doi: 10.1158/0008-5472.CAN-12-4403 PMID: 23659968
5. Saji H, Tsuboi M, Shimada Y, Kato Y, Hamanaka W, Kudo Y, et al. Gene expression profiling and molecular pathway analysis for the identification of early-stage lung adenocarcinoma patients at risk for early recurrence. Oncol Rep. 2013; 29:1902–6. doi: 10.3892/or.2013.2332 PMID: 23468017
6. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009; 136:629–41. doi: 10.1016/j.cell.2009.02.006 PMID: 19239885
7. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12:861–74. doi: 10.1038/nrg3074 PMID: 22094949
8. Chen S, Li P, Li J, Wang Y, Du Y, Chen X, et al. MiR-144 Inhibits Proliferation and Induces Apoptosis and Autophagy in Lung Cancer Cells by Targeting TIGAR. Cell Physiol Biochem. 2015; 35:997–1007. doi: 10.1159/000369755 PMID: 25660220
9. Li J, Li P, Chen T, Gao G, Chen X, Du Y, et al. Expression of microRNA-96 and its potential functions by targeting FOXO3 in non-small cell lung cancer. Tumour Biol. 2015; 36:685–92. doi: 10.1007/s13277-014-2698-y PMID: 25286764
10. Pottier N, Maurin T, Chevalier B, Puisségur MP, Lebrigand K, Robbe-Sermesant K, et al. Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions. PLoS One. 2009; 4:e6718. doi: 10.1371/journal.pone.0006718 PMID: 19701459
11. Wang Y, Zhong H, Xie X, Chen CY, Huang D, Shen L, et al. Long noncoding RNA derived from CD244 signaling epigenetically controls CD8+ T-cell immune responses in tuberculosis infection. Proc Natl Acad Sci U S A. 2015; 112:E883–92. doi: 10.1073/pnas.1501662112 PMID: 25605004
12. Wang P, Xue Y, Han Y, Lin L, Wu C, Xu S, et al. The STAT3-binding long noncoding RNA Inc-DC controls human dendritic cell differentiation. Science. 2014; 344:310–3. doi: 10.1126/science.1251456 PMID: 24744378
13. Hung CL, Wang LY, Yu YL, Chen HW, Srivastava S, Petrovics G, et al. A long noncoding RNA connects c-Myc to tumor metabolism. Proc Natl Acad Sci U S A. 2014; 111(52):18697–702. doi: 10.1073/pnas.1415669112 PMID: 25152540
14. Bida O, Gidoni M, Ideses D, Efroni S, Ginsberg D. A novel mitosis-associated IncRNA, MA-linc1, is required for cell cycle progression and sensitizes cancer cells to Paclitaxel. Oncotarget. 2015; 6:27880–90. doi: 10.18632/oncotarget.4944 PMID: 26337085
15. Xia T, Chen S, Jiang Z, Shao Y, Jiang X, Li P, et al. Long noncoding RNA FER1L4 suppresses cancer cell growth by acting as a competing endogenous RNA and regulating PTEN expression. Sci Rep. 2015; 5:13445. doi: 10.1038/srep13445 PMID: 26306906
16. Cui W, Qian Y, Zhou X, Lin Y, Jiang J, Chen J, et al. Discovery and characterization of long intergenic non-coding RNAs (lincRNA) module biomarkers in prostate cancer: an integrative analysis of RNA-Seq data. BMC Genomics. 2015; 16 Suppl 7:S3. doi: 10.1186/1471-2164-16-S7-S3 PMID: 26105840
17. Li J, Ye L, Mansel RE, Jiang WG. Potential prognostic value of repulsive guidance molecules in breast cancer. Anticancer Res. 2011; 31:1703–11. PMID: 21617229

18. Li J, Ye L, Kynaston HG, Jiang WG. Repulsive guidance molecules, novel bone morphogenetic protein co-receptors, are key regulators of the growth and aggressiveness of prostate cancer cells. Int J Oncol. 2012; 40:544–5. doi: 10.3892/ijo.2011.1251 PMID: 22076499

19. Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003; 22:8031–41. PMID: 12970751

20. Wang WB, Böing S, Zhou XQ, Ji P, Dong Y, Yao Q, et al. Identification of metastasis-associated genes in early stage non-small cell lung cancer by subtractive hybridization. Sheng Wu Hua Xue Yu Sheng Wu Li Xue Bao (Shanghai). 2002; 34:273–8.

21. Schmidt LH, Speiker T, Koschmieder S, Humberg J, Jungen D, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011; 6:1984–92. doi: 10.1097/JTO.0b013e3182307eac PMID: 22086988

22. Khandelwal A, Bacolla A, Vasquez KM, Jain A. Long non-coding RNA: A new paradigm for lung cancer. Mol Carcinog. 2015; 54:1235–51. doi: 10.1002/mc.22362 PMID: 2633907

23. Qiu JJ, Lin YY, Ye LC, Ding JX, Feng WW, Jin HY, et al. Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer. Gynecol Oncol. 2014; 134:121–8. doi: 10.1016/j.ygyno.2014.03.556 PMID: 24662839

24. Kim HJ, Lee DW, Yim GW, Nam EJ, Kim S, Kim SW, et al. Long non-coding RNA HOTAIR is associated with human cervical cancer progression. Int J Oncol. 2015; 46:521–30. doi: 10.3892/ijo.2014.2758 PMID: 25405331

25. Berrondo C, Flax J, Kucherov V, Siebert A, Osinski T, Rosenberg A, et al. Expression of the Long Non-Coding RNA HOTAIR Correlates with Disease Progression in Bladder Cancer Patient Urinary Exosomes. PLoS One. 2016; 11:e0147236. doi: 10.1371/journal.pone.0147236 PMID: 26800519

26. Nakagawa T, Endo H, Yokoyama M, Abe J, TamakI T, Tanaka N, et al. Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer. Biochem Biophys Res Commun. 2013; 436:319–24. doi: 10.1016/j.bbrc.2013.05.101 PMID: 23743197

27. Liu XH, Liu ZL, Sun M, Liu J, Wang ZX, De W. The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer. BMC Cancer. 2013; 13:464. doi: 10.1186/1471-2407-13-464 PMID: 24103700

28. Ono H, Motoi N, Nagano H, Miyachi U, Ushijima M, Matsuura M, et al. Large noncoding RNA HOTAIR is relevant to cellular proliferation, invasiveness, and clinical relapse in small-cell lung cancer. Cancer Med. 2014; 3:632–42. doi: 10.1002/cam4.220 PMID: 24591352

29. Fang S, Gao H, Tong Y, Yang J, Tang R, Niu Y, et al. Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells. Lab Invest. 2016; 96:60–8. doi: 10.1038/labinv.2015.125 PMID: 26707824

30. Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W, et al. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregulation of p21(WAF1/CIP1) expression. PLoS One. 2013; 8:e77293. doi: 10.1371/journal.pone.0077293 PMID: 24155936

31. Severyn CJ, Shinde U, Rotwein P. Molecular biology, genetics and biochemistry of the repulsive guidance molecule family. Biochem J. 2009; 422:393–403. doi: 10.1042/BJ20090978 PMID: 19698085

32. Monnier PP, Sierra A, Macchi P, Deltinghoff L, Andersen JS, Mann M, et al. RGM is a repulsive guidance molecule for retinal axons. Nature. 2002; 419:392–5. doi: 10.1038/nature01193 PMID: 12353034

33. Niederkofler V, Salie R, Sigrist M, Arber S. Repulsive guidance molecule (RGM) gene function is required for neural tube closure but not retinal topography in the mouse visual system. J Neurosci. 2004; 24:808–12. doi: 10.1523/JNEUROSCI.0031-04.2004 PMID: 15228955

34. Babitt JL, Zhang Y, Samad TA, Xia Y, Tang J, Campagna JA, et al. The Role of Long Noncoding RNA RGMB-AS1 in Lung Adenocarcinoma. PLoS ONE. 2013; 8:e77293. doi: 10.1371/journal.pone.0077293 PMID: 24155936

35. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, et al. Bone morphogenetic protein signaling by hemojulin regulates hepcidin expression. Nat Genet. 2006; 38:531–9. PMID: 16604073

36. Samad TA, Srinivasan A, Karchewski LA, Jeong SJ, Campagna JA, Ji RR, et al. DRAGON: a member of the repulsive guidance molecule-related family of neuronal- and muscle-expressed membrane proteins is regulated by DRG11 and has neuronal adhesive properties. J Neurosci. 2004; 24:2027–36. PMID: 14985445
37. Kanomata K, Kokabu S, Nojima J, Fukuda T, Katagiri T. DRAGON, a GPI-anchored membrane protein, inhibits BMP signaling in C2C12 myoblasts. Genes Cells. 2009; 14:695–702. doi: 10.1111/j.1365-2443.2009.01302.x PMID: 19422419

38. Li J, Ye L, Sanders AJ, Jiang WG. Repulsive guidance molecule B (RGMB) plays negative roles in breast cancer by coordinating BMP signaling. J Cell Biochem. 2012; 113:2523–31. doi: 10.1002/jcb.24128 PMID: 22415859